The listeria monocytogenes infections treatment market size has grown strongly in recent years. It will grow from $4.52 billion in 2023 to $4.79 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. Historical growth in addressing Listeria monocytogenes infections was largely driven by factors such as the implementation of stricter food safety regulations, a rise in the frequency of foodborne illnesses, advancements in diagnostic methods, educational awareness programs, and improvements in healthcare infrastructure.
The listeria monocytogenes infections treatment market size is expected to see strongly grown in the next few years. It will grow to $5.86 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. Anticipated growth in managing Listeria monocytogenes infections in the forecast period is linked to several factors, including the globalization of food supply chains, ongoing research and development efforts in antimicrobial treatments, shifts in dietary patterns, increased international collaboration in healthcare, and a heightened focus on public health preparedness.
The listeria monocytogenes infection treatment market is poised for growth owing to the increasing prevalence of foodborne diseases. These illnesses, stemming from consuming contaminated food or beverages, encompass concerns related to listeria monocytogenes infections. The treatment for such infections mitigates risks and curbs the severity of the disease. Notably, in December 2022, the European Food Safety Authority reported a 29.8% surge in foodborne incidents, recording approximately 4,005 cases in 2021 compared to the previous year. This escalation underscores the pivotal role of the rising foodborne disease incidence in propelling the listeria monocytogenes infection treatment market.
Government-led initiatives in healthcare research and development are set to bolster the listeria monocytogenes infection treatment market. These initiatives encompass targeted actions, policies, or funding programs by government entities to address healthcare concerns. Notably, the UK government's commitment of £260 million (US $270.65 million) in 2022 towards healthcare research and manufacturing stands as a testament to this drive. This substantial funding aims to support NHS-led health research, privacy-preserving platforms for diagnostics and treatment, and the expansion of life sciences manufacturing. Such governmental backing significantly impacts the growth trajectory of the listeria monocytogenes infection treatment market. The listeria monocytogenes infection treatment market is set to expand further owing to the escalating healthcare expenditure. This expenditure represents the cumulative spending on healthcare-related goods and services within an economy or healthcare system. The increased allocation of funds plays a pivotal role in fostering the development and accessibility of listeria monocytogenes infection treatment. For instance, in November 2022, healthcare expenditure in Canada surged to $331 billion, marking an increase of 0.8% from the previous year's 7.6%. This upward trend in healthcare expenditure significantly fuels the growth dynamics of the listeria monocytogenes infection treatment market.
Key companies in the listeria monocytogenes infection treatment market are prioritizing innovation, exemplified by products like Microgen Listeria-ID. This microbiological test, launched by Gold Standard Diagnostics in April 2023, enables the detection and confirmation of Listeria bacteria in food and environmental samples. Microgen Listeria-ID offers a comprehensive identification process, swiftly detecting and distinguishing Listeria spp species without additional materials. Renowned for its rapid and reliable identification, this test significantly expedites quality control measures and monitoring in food processing facilities, contributing to market revenue and efficiency.
In September 2022, Team Arnav Foundation, a US-based nonprofit group focused on finding treatment for juvenile sarcoma cancer, partnered with OS Therapies LLC. With this partnership, Team Arnav Foundation supports the phase IIb trial of OST-HER2 (Listeria monocytogenes) in recurrent, resected osteosarcoma. Additionally, Team Arnav's primary mission is to fund research that would lead to better treatments, higher cure rates, and reduced side effects for patients with malignant bone and soft tissue cancers. OS Therapies LLC is a US-based clinical-stage therapeutic company that develops immunotherapies based on live attenuated listeria monocytogenes (Lm) for solid tumors such as osteosarcoma.
Major companies operating in the listeria monocytogenes infections treatment market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Biogen Inc., Vertex Pharmaceuticals Incorporated, Fresenius Kabi AG, Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., ZydusCadila Health Care Ltd., Emergent Bio Solutions Inc., Wockhardt Ltd., Hainan Poly Pharm Co. Ltd., Novel Laboratories Inc., Bionpharma Inc., LimmaTech Biologics AG.
North America was the largest region in the listeria monocytogenes infections treatment market in 2023. The regions covered in the listeria monocytogenes infections treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the listeria monocytogenes infections treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main classes of drugs used for listeria monocytogenes infections treatment are Ampicillin, Gentamicin, Vancomycin, and others. Several types of infections include gastroenteritis, endocarditis, meningitis, bacteremia, and brain abscess. The drugs can be administered through various modes, such as oral, injectable, and other modes and are used by several end users, including hospitals, home care, specialty clinics, and others.
The listeria monocytogenes infections treatment market research report is one of a series of new reports provides listeria monocytogenes infections treatment market statistics, including listeria monocytogenes infections treatment industry global market size, regional shares, competitors with a listeria monocytogenes infections treatment market share, detailed listeria monocytogenes infections treatment market segments, market trends and opportunities, and any further data you may need to thrive in the listeria monocytogenes infections treatment industry. This listeria monocytogenes infections treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The listeria monocytogenes infections treatment market consists of revenues earned by entities by provide services such as diagnosis, antibiotic therapy, medical consultations, and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. The listeria monocytogenes infections treatment market also includes sales of penicillin G, meropenem, and trimethoprim-sulfamethoxazole (TMP-SMX). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The listeria monocytogenes infections treatment market size is expected to see strongly grown in the next few years. It will grow to $5.86 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. Anticipated growth in managing Listeria monocytogenes infections in the forecast period is linked to several factors, including the globalization of food supply chains, ongoing research and development efforts in antimicrobial treatments, shifts in dietary patterns, increased international collaboration in healthcare, and a heightened focus on public health preparedness.
The listeria monocytogenes infection treatment market is poised for growth owing to the increasing prevalence of foodborne diseases. These illnesses, stemming from consuming contaminated food or beverages, encompass concerns related to listeria monocytogenes infections. The treatment for such infections mitigates risks and curbs the severity of the disease. Notably, in December 2022, the European Food Safety Authority reported a 29.8% surge in foodborne incidents, recording approximately 4,005 cases in 2021 compared to the previous year. This escalation underscores the pivotal role of the rising foodborne disease incidence in propelling the listeria monocytogenes infection treatment market.
Government-led initiatives in healthcare research and development are set to bolster the listeria monocytogenes infection treatment market. These initiatives encompass targeted actions, policies, or funding programs by government entities to address healthcare concerns. Notably, the UK government's commitment of £260 million (US $270.65 million) in 2022 towards healthcare research and manufacturing stands as a testament to this drive. This substantial funding aims to support NHS-led health research, privacy-preserving platforms for diagnostics and treatment, and the expansion of life sciences manufacturing. Such governmental backing significantly impacts the growth trajectory of the listeria monocytogenes infection treatment market. The listeria monocytogenes infection treatment market is set to expand further owing to the escalating healthcare expenditure. This expenditure represents the cumulative spending on healthcare-related goods and services within an economy or healthcare system. The increased allocation of funds plays a pivotal role in fostering the development and accessibility of listeria monocytogenes infection treatment. For instance, in November 2022, healthcare expenditure in Canada surged to $331 billion, marking an increase of 0.8% from the previous year's 7.6%. This upward trend in healthcare expenditure significantly fuels the growth dynamics of the listeria monocytogenes infection treatment market.
Key companies in the listeria monocytogenes infection treatment market are prioritizing innovation, exemplified by products like Microgen Listeria-ID. This microbiological test, launched by Gold Standard Diagnostics in April 2023, enables the detection and confirmation of Listeria bacteria in food and environmental samples. Microgen Listeria-ID offers a comprehensive identification process, swiftly detecting and distinguishing Listeria spp species without additional materials. Renowned for its rapid and reliable identification, this test significantly expedites quality control measures and monitoring in food processing facilities, contributing to market revenue and efficiency.
In September 2022, Team Arnav Foundation, a US-based nonprofit group focused on finding treatment for juvenile sarcoma cancer, partnered with OS Therapies LLC. With this partnership, Team Arnav Foundation supports the phase IIb trial of OST-HER2 (Listeria monocytogenes) in recurrent, resected osteosarcoma. Additionally, Team Arnav's primary mission is to fund research that would lead to better treatments, higher cure rates, and reduced side effects for patients with malignant bone and soft tissue cancers. OS Therapies LLC is a US-based clinical-stage therapeutic company that develops immunotherapies based on live attenuated listeria monocytogenes (Lm) for solid tumors such as osteosarcoma.
Major companies operating in the listeria monocytogenes infections treatment market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Biogen Inc., Vertex Pharmaceuticals Incorporated, Fresenius Kabi AG, Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., ZydusCadila Health Care Ltd., Emergent Bio Solutions Inc., Wockhardt Ltd., Hainan Poly Pharm Co. Ltd., Novel Laboratories Inc., Bionpharma Inc., LimmaTech Biologics AG.
North America was the largest region in the listeria monocytogenes infections treatment market in 2023. The regions covered in the listeria monocytogenes infections treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the listeria monocytogenes infections treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main classes of drugs used for listeria monocytogenes infections treatment are Ampicillin, Gentamicin, Vancomycin, and others. Several types of infections include gastroenteritis, endocarditis, meningitis, bacteremia, and brain abscess. The drugs can be administered through various modes, such as oral, injectable, and other modes and are used by several end users, including hospitals, home care, specialty clinics, and others.
The listeria monocytogenes infections treatment market research report is one of a series of new reports provides listeria monocytogenes infections treatment market statistics, including listeria monocytogenes infections treatment industry global market size, regional shares, competitors with a listeria monocytogenes infections treatment market share, detailed listeria monocytogenes infections treatment market segments, market trends and opportunities, and any further data you may need to thrive in the listeria monocytogenes infections treatment industry. This listeria monocytogenes infections treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The listeria monocytogenes infections treatment market consists of revenues earned by entities by provide services such as diagnosis, antibiotic therapy, medical consultations, and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. The listeria monocytogenes infections treatment market also includes sales of penicillin G, meropenem, and trimethoprim-sulfamethoxazole (TMP-SMX). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary2. Listeria Monocytogenes Infections Treatment Market Characteristics3. Listeria Monocytogenes Infections Treatment Market Trends and Strategies31. Global Listeria Monocytogenes Infections Treatment Market Competitive Benchmarking32. Global Listeria Monocytogenes Infections Treatment Market Competitive Dashboard33. Key Mergers and Acquisitions in the Listeria Monocytogenes Infections Treatment Market
4. Listeria Monocytogenes Infections Treatment Market - Macro Economic Scenario
5. Global Listeria Monocytogenes Infections Treatment Market Size and Growth
6. Listeria Monocytogenes Infections Treatment Market Segmentation
7. Listeria Monocytogenes Infections Treatment Market Regional and Country Analysis
8. Asia-Pacific Listeria Monocytogenes Infections Treatment Market
9. China Listeria Monocytogenes Infections Treatment Market
10. India Listeria Monocytogenes Infections Treatment Market
11. Japan Listeria Monocytogenes Infections Treatment Market
12. Australia Listeria Monocytogenes Infections Treatment Market
13. Indonesia Listeria Monocytogenes Infections Treatment Market
14. South Korea Listeria Monocytogenes Infections Treatment Market
15. Western Europe Listeria Monocytogenes Infections Treatment Market
16. UK Listeria Monocytogenes Infections Treatment Market
17. Germany Listeria Monocytogenes Infections Treatment Market
18. France Listeria Monocytogenes Infections Treatment Market
19. Italy Listeria Monocytogenes Infections Treatment Market
20. Spain Listeria Monocytogenes Infections Treatment Market
21. Eastern Europe Listeria Monocytogenes Infections Treatment Market
22. Russia Listeria Monocytogenes Infections Treatment Market
23. North America Listeria Monocytogenes Infections Treatment Market
24. USA Listeria Monocytogenes Infections Treatment Market
25. Canada Listeria Monocytogenes Infections Treatment Market
26. South America Listeria Monocytogenes Infections Treatment Market
27. Brazil Listeria Monocytogenes Infections Treatment Market
28. Middle East Listeria Monocytogenes Infections Treatment Market
29. Africa Listeria Monocytogenes Infections Treatment Market
30. Listeria Monocytogenes Infections Treatment Market Competitive Landscape and Company Profiles
34. Listeria Monocytogenes Infections Treatment Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
Listeria Monocytogenes Infections Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on listeria monocytogenes infections treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for listeria monocytogenes infections treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of covid 19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:
1) by Drug Class: Ampicillin; Gentamicin; Vancomycin; Other Drug Classes2) by Type of Infection: Gastroenteritis; Endocarditis; Meningitis; Bacteremia; Brain Abscess
3) by Mode of Administration: Oral; Injectable; Other Mode of Administrations
4) by End Users: Hospitals; Home Care; Specialty Clinics; Other End Users
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi S.A
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Methodology
LOADING...
